Collaboration to explore the immunoregulation of NK and T cells within the tumor microenvironment (TME) by CAPTN-3, with the goal of enhancing ...

Scientists have progressed from merely provoking an anti-cancer immune response to designing it ...

Biocytogen (HKEX: 02315), a global biotech company dedicated to discovering and developing novel antibody therapeutics, announced the licensing of its fully human antibodies to ...

Acquisition to strengthen key pillar of BioNTech’s oncology strategy aimed at establishing BNT327 as a pan-tumor technology platformfor the ...

Ypsilon Therapeutics, a portfolio company of 82VS, Alloy’s venture studio, has been awarded $2.7 million in seed funding from ...

This article explores how broadly neutralizing antibodies are being researched, not only for their potential in the ...

Induces potent and long-lasting immune responses to defined antigens or whole pathogens (particles), mainly through the ...

The European Medicines Agency has recommended three new medicines to treat breast and cervical cancer and ...

Global Gamma Delta T Cell Cancer Therapy Market Opportunity and Clinical Trials Insight 2030 Report Conclusions: Download ...

The FDA has approved a new treatment for patients with a common form of breast cancer that has spread to other parts of the ...

Ipsen and Sutro Biopharma entered a global licensing deal for STRO-003, an ADC targeting ROR1, overexpressed in cancers, marking Ipsen's first ADC portfolio addition.United States, New York, Jan. 31, ...